<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971594</url>
  </required_header>
  <id_info>
    <org_study_id>AG0120</org_study_id>
    <secondary_id>K01AG021457</secondary_id>
    <nct_id>NCT00971594</nct_id>
  </id_info>
  <brief_title>Age, Lifestyle, Muscle Mechanisms in Insulin Resistance</brief_title>
  <official_title>Age, Lifestyle, Muscle Mechanisms in Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the mechanisms by which physical inactivity and&#xD;
      obesity alter skeletal muscle insulin signaling to cause insulin resistance and increase the&#xD;
      development of impaired glucose tolerance (IGT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aging is associated with a progressive development of impaired glucose tolerance (IGT), due&#xD;
      to an increased peripheral tissue resistance to the action of insulin. Insulin resistance, a&#xD;
      common state in both obese and sedentary individuals, eventually leads to the development of&#xD;
      glucose intolerance, and type 2 diabetes with aging. Even in the absence of diabetes, insulin&#xD;
      resistance is a key feature in various metabolic abnormalities that increase the risk for&#xD;
      developing cardiovascular disease (CVD). Previous studies demonstrate improvements in glucose&#xD;
      tolerance and glucose utilization following moderate energy restriction coupled with moderate&#xD;
      intensity AEX. WL, through behavioral modification of diet and aerobic exercise (AEX), is&#xD;
      perhaps the most effective way to treat as well as prevent insulin resistance and its&#xD;
      associated metabolic complications of IGT and type 2 diabetes. Although these studies&#xD;
      demonstrate the beneficial effect of weight loss (WL) and AEX on glucose tolerance and&#xD;
      insulin action, not much is known about the cellular and molecular mechanisms by which these&#xD;
      nonpharmacologic treatments improve glucose utilization in high-risk obese older individuals.&#xD;
&#xD;
      This study seeks to determine the cellular mechanisms by which aerobic exercise and weight&#xD;
      loss alter skeletal muscle insulin signaling to improve insulin action in older glucose&#xD;
      intolerant individuals. A second purpose is to determine whether certain genes (hereditary&#xD;
      information) affect the way the body utilizes glucose in response to exercise and weight&#xD;
      loss. In addition, adipose tissue is increasingly recognized as more than an inert depot&#xD;
      serving not only to accept and store excess energy in the form of triglycerides, but also to&#xD;
      secrete hormones and adipokines that have substantial effects on lipid and glucose&#xD;
      metabolism. Furthermore, there are depot differences in metabolic function, as well as&#xD;
      adipokine content. However, the physiology both underlying and consequential to these&#xD;
      observations remains unknown. Thus, a third aim is to examine the effects of obesity on&#xD;
      regional adipokine secretion and expression, and the relationship of adipokines to insulin&#xD;
      resistance and the metabolic syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin stimulated glucose disposal</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Content and activity of insulin signaling proteins from muscle biopsies</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight/Composition</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other biomarkers (such as glucose, insulin etc)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <condition>Glucose Intolerance</condition>
  <condition>Exercise Capacity</condition>
  <arm_group>
    <arm_group_label>WL+AEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight loss plus aerobic exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary counseling</intervention_name>
    <description>1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk</description>
    <arm_group_label>WL+AEX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>AEX</intervention_name>
    <description>Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.</description>
    <arm_group_label>WL+AEX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men older than 50 yrs of age&#xD;
&#xD;
          -  Non-smoking (more than 5 years)&#xD;
&#xD;
          -  BMI greater than 25 kg/m2 and less than 50 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CAD, CHF, Myocardial infarction within 6 months or other symptomatic heart disease&#xD;
&#xD;
          -  History of stroke, peripheral arterial disease&#xD;
&#xD;
          -  Currently being treated for active cancer&#xD;
&#xD;
          -  On oral agents or insulin therapy for diabetes&#xD;
&#xD;
          -  Poorly controlled Dyslipidemia (abnormal concentration of lipids or lipoproteins in&#xD;
             the blood)&#xD;
&#xD;
          -  Poorly controlled hypertension (BP &gt; 180/95)&#xD;
&#xD;
          -  Other systematic disorders that are not medically treated and stable&#xD;
&#xD;
          -  Physical impairment limiting normal activity and other contraindications to exercise&#xD;
&#xD;
          -  Aerobically conditioned&#xD;
&#xD;
          -  Abnormal response to exercise (chest pain, significant arrhythmias, extreme shortness&#xD;
             of breath, cyanosis, exercising BP &gt; 240/120)&#xD;
&#xD;
          -  Taking warfarin/coumadin&#xD;
&#xD;
          -  Taking oral steroids&#xD;
&#xD;
          -  Abnormal renal function or liver function&#xD;
&#xD;
          -  Chronic pulmonary disease severe enough to require oxygen&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  MMSE &lt; 24, dementia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyndon Joseph, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </reference>
  <reference>
    <citation>Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol (1985). 2004 Jan;96(1):101-6. Epub 2003 Sep 12.</citation>
    <PMID>12972442</PMID>
  </reference>
  <reference>
    <citation>Deshmukh AS, Hawley JA, Zierath JR. Exercise-induced phospho-proteins in skeletal muscle. Int J Obes (Lond). 2008 Sep;32 Suppl 4:S18-23. doi: 10.1038/ijo.2008.118. Review.</citation>
    <PMID>18719593</PMID>
  </reference>
  <reference>
    <citation>Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic. Clin Chest Med. 2009 Sep;30(3):415-44, vii. doi: 10.1016/j.ccm.2009.05.001. Review.</citation>
    <PMID>19700042</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>September 2, 2009</last_update_submitted>
  <last_update_submitted_qc>September 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alice S. Ryan, PhD</name_title>
    <organization>University of Maryland</organization>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

